Angelina Jolie, inherited breast cancer and the BRCA1 gene

Angelina Jolie

Actress Angelina Jolie has had surgery to prevent breast cancer

The news today is full of reaction to US actress Angelina Jolie’s decision to have surgery to reduce her chances of breast cancer.

She made this difficult decision because, having lost her mother to ovarian cancer, she discovered she carries a faulty copy of the BRCA1 gene – which put her at very high risk of getting both forms of the disease.

If you haven’t read her brave and thoughtful piece in the New York Times, it’s worth doing so.

But in the light of the considerable interest, and the fact that many people will undoubtedly have questions, we wanted to pull together a few quick thoughts and facts on the topic of inherited breast cancer generally, and the BRCA1 gene specifically.

Continue reading

Clinical trials and Parliamentary tribulations

Professor Peter Johnson representing Cancer Research UK

Professor Peter Johnson representing Cancer Research UK

Clinical trials are vital – they’re how we know which treatments work, how best to use them, and what the side effects are. So running trials quickly and effectively, and sharing their results, is essential if we’re to continue our progress in beating cancer.

On Monday, the House of Commons Science and Technology Committee – a group of MPs that scrutinises the Government’s science policies – held an evidence session with academic and charitable research funders, to examine issues around clinical trials.

Our chief clinician, Professor Peter Johnson, was invited to give our view on what needs to be done, alongside representatives from the Wellcome Trust, the Medical Research Council and Association of Medical Research Charities.

You can watch the entire session on the Government’s website here.

Continue reading

Innovative drug development fund backs first major project

Molecular machinery of a dividing cell. Image courtesy of Wikimedia Commons

MPS1 inhibitors block a molecule involved in cell division.

Last year we were extremely excited to launch an innovative fund to bring new cancer drugs to patients.

Today we’re pleased to reveal that the fund has given the green light to its first project, aimed at accelerating the development of a promising group of compounds called MPS1 inhibitors into effective new cancer drugs.

The £50 million fund has been developed to address the sobering reality that the process of turning promising investigational drugs into ‘real life’ treatments for cancer patients is very often unsuccessful. The fund, half of which is provided through our commercial company Cancer Research Technology (CRT), is central to our strategy to make sure that exciting drug discoveries don’t languish at the lab bench, but are given every chance to be transformed into future cancer cures.

Called the CRT Pioneer Fund, it’s being run by independent management firm Sixth Element Capital, who have spent the last few months selecting exciting drug discovery opportunities from around the country.

Read on to find out why work on MPS1 inhibitors by researchers at The Institute of Cancer Research, London, piqued their interest and led to the first grant from the Pioneer Fund.

Continue reading

New type of bowel cancer discovered – but what does it mean?

Bowel cancer cells

Our researchers have found a new sub-type of bowel cancer

Thanks to advances in research over the years, we know more about cancer than ever before, with new discoveries being made all the time. In some cases this knowledge has led to life-saving new treatments. In others, it causes frustration and head-scratching until more pieces of the puzzle fall into place.

For example, why do some patients with the same type of cancer respond to a treatment but others don’t? And what makes some cancers grow and spread aggressively while others are less dangerous?

Thanks to research, answers to these questions are coming. Much of this progress hinges on the use of new technology to analyse the faulty genes in cancer cells, enabling researchers and doctors to characterise the molecular fingerprint of an individual person’s cancer and select the most appropriate treatment.

As an example, last year our scientists showed that, based on the genetic makeup of each patient’s  disease, breast cancer can be divided into at least ten distinct subtypes, each with different outlooks and responses to treatment.

Now it’s bowel cancer’s turn under the spotlight, as researchers at our Cambridge Institute – along with colleagues in the Netherlands and Oxford – have discovered a new subtype of bowel cancer, which has a worse outcome than other types and is resistant to current targeted treatments.

Published in the journal Nature Medicine, their results have big implications for patients and future research. Continue reading

Cancer care in the new NHS in England

NHS logo

Changes are afoot in the NHS – what will they mean for cancer patients?

As of Monday (1st April) the Government’s reform of the NHS became a reality, with the Health and Social Care Act coming into force.

We’ve blogged a number of times about our views on the reforms as they took shape over the last couple of years, and more recently about our report on the state of cancer services during transition to the new system.

But now that the reforms are actually in place, and more of the detail has emerged, we thought we would take this opportunity to look at how the new NHS will work for cancer patients.

Continue reading

Expert Opinion – The challenges of lung cancer

Professor Dean Fennell

Professor Dean Fennell

One of our leading experts in lung cancer, Professor Dean Fennell, shares his thoughts on this devastating disease.

Lung cancer is an enormous health burden both in the UK and globally. It’s incredibly common and kills roughly 35,000 people every year in the UK alone – and more than 1.3 million people worldwide.

But despite its prevalence, and the strain it places on healthcare, progress in treating lung cancer has been slow.

Historically, the disease has always been viewed as one that’s difficult to treat, and this has led to a general lack of interest in trying to move treatments forwards. The reluctance to carry out research into lung cancer was further increased by the perception that we’d hit a plateau with treatment about 10 years ago, and many people in the field felt that we’d reached the limit of what we could achieve in this disease.

Continue reading

News digest – Budget, bowel screening, Bluetooth, kids smoking and more

UK newspapers

Read our news digest

Continue reading